Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
betamethasone + prednisolone
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
Betamethasone + prednisolone is a combination of two corticosteroids used to treat various inflammatory conditions. Both medications work by suppressing inflammation and modulating the immune system. In clinical studies, this combination has been compared for efficacy in treating conditions such as seasonal rhinoconjunctivitis, with findings suggesting similar symptom control but different adrenal suppression profiles.
- Other names
- prednisolonebetamethasonecorticosteroid treatment for acute unilateral vestibulopathy
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on betamethasone + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on betamethasone + prednisolone.